Harrow Inc (NASDAQ:HROW) is set to release its Q2 2025 earnings on Aug 11, 2025. The consensus estimate for Q2 2025 revenue ...

Harrow has received a total of 2 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $68.0, the consensus suggests a potential 104.76% upside.

Harrow (HROW) shares soared 11.4% in the last trading session to close at $34.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright’s 5th Annual Ophthalmology Conference on Wednesday, ...